Regenerating Heart Muscle Cells in the Hope of Treating Heart Failure

Two chemicals that improve the ability to transform scar tissue in a heart into healthy, beating heart muscle have been identified by scientists.

Heart failure afflicts 5.7 million Americans, costs the country $30.7 billion every year, and has no cures. When heart muscle is damaged, the body is unable to repair the dead or injured cells.

Scientists at the Gladstone Institutes are exploring cellular reprogramming - turning one type of adult cell into another - in the heart as a way to regenerate muscle cells in the hopes of treating, and ultimately curing, heart failure.

Imaging Test can Accurately Detect Amyloid-Related Heart Failure
Transthyretin-related cardiac amyloidosis (ATTR-CA) is a condition in which a protein breaks down and forms fibrils that deposit in organs and tissues, leading to heart failure.

‘Two newly identified chemicals improved the speed, quantity, and quality of direct cardiac reprogramming, bringing the technology one step closer to regenerating damaged hearts.’

Gladstone scientists identified two chemicals that improve their ability to transform scar tissue in a heart into healthy, beating heart muscle. The new discovery advances efforts to find new and effective treatments for heart failure.

It takes only three transcription factors - proteins that turn genes on or off in a cell - to reprogram connective tissue cells into heart muscle cells in a mouse. After a heart attack, connective tissue forms scar tissue at the site of the injury, contributing to heart failure.

The three factors, Gata4, Mef2c, and Tbx5 (GMT), work together to turn heart genes on in these cells and turn other genes off, effectively regenerating a damaged heart with its own cells. But the method is not foolproof - typically, only 10% of cells fully convert from scar tissue to muscle.

Congestive Heart Failure (Congestive Cardiac Failure) Current Management
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump that can deliver oxygen rich blood to the body.

In the new study, published in Circulation, Gladstone scientists tested 5500 chemicals to try to improve this process. They identified two chemicals that increased the number of heart cells created by eight-fold. Moreover, the chemicals sped up the process of cell conversion, achieving in one week what used to take six to eight weeks.

"While our original process for direct cardiac reprogramming with GMT has been promising, it could be more efficient," said senior author Deepak Srivastava, director of the Gladstone Institute of Cardiovascular Disease. "With our screen, we discovered that chemically inhibiting two biological pathways active in embryonic formation improves the speed, quantity, and quality of the heart cells produced from our original process."

Increased Caffeine Intake Among Heart Failure Patients Did Not Induce Arrhythmias
The clinical trial study published in JAMA Internal Medicine stated that high doses of caffeine did not induce arrhythmias in heart failure patients.

The first chemical inhibits a growth factor that helps cells grow and divide and is important for repairing tissue after injury. The second chemical inhibits an important pathway that regulates heart development. By combining the two chemicals with GMT, the researchers successfully regenerated heart muscle and greatly improved heart function in mice that had suffered a heart attack.

The scientists also used the chemicals to improve direct cardiac reprogramming of human cells, which is a more complicated process that requires additional factors. The two chemicals enabled the researchers to simplify the process bringing them one step closer to better treatments for heart failure.

Researchers Identify Two Key Proteins That Control Heart Growth
Researchers have identified how two proteins control the growth of the heart and its adaptation to high blood pressure.

"Heart failure afflicts many people worldwide, and we still do not have an effective treatment for patients suffering from this disease," said Tamer Mohamed, first author on the study and a former postdoctoral scholar at Gladstone. "With our enhanced method of direct cardiac reprogramming, we hope to combine gene therapy with drugs to create better treatments for patients suffering from this devastating disease."

Source-Eurekalert